Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.AstraZeneca reported strong Q3 sales and raised its 2024 outlook, while avoiding questions about China and announcing plans to invest $2 billion in the U.S. market. Bayer's earnings were described as "not pretty" by CEO Bill Anderson, leading to a decline in stock value. Roche signed a potential $1.8 billion deal with Flare for cancer treatment, while 23andMe cut its ...